Pages that link to "Q37180600"
Jump to navigation
Jump to search
The following pages link to Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function (Q37180600):
Displaying 50 items.
- New and emerging disease modifying therapies for multiple sclerosis (Q22242305) (← links)
- Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (Q24630092) (← links)
- Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities (Q26781389) (← links)
- Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis (Q28087414) (← links)
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (Q28243804) (← links)
- Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders (Q28740884) (← links)
- Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. (Q30245002) (← links)
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue (Q30276550) (← links)
- The role of therapeutic plasma exchange in poisonings and intoxications (Q30455129) (← links)
- Neurologic indications for therapeutic plasma exchange: 2011 update (Q30455391) (← links)
- Neurologic indications for therapeutic plasma exchange: 2013 update (Q30458271) (← links)
- CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier (Q30541389) (← links)
- Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis (Q30659100) (← links)
- Extended interval dosing of natalizumab in multiple sclerosis (Q31049360) (← links)
- Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis (Q33573208) (← links)
- Natalizumab Therapy of Multiple Sclerosis (Q33704298) (← links)
- Natalizumab in Multiple Sclerosis: Long-Term Management (Q33754882) (← links)
- Progressive multifocal leukoencephalopathy and other forms of JC virus disease (Q33763351) (← links)
- Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System (Q33770508) (← links)
- The use of natalizumab for multiple sclerosis (Q33879159) (← links)
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis (Q33893285) (← links)
- Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis (Q34122035) (← links)
- Risk stratification and mitigation multiple sclerosis. (Q34155446) (← links)
- Toxicities of immunosuppressive treatment of autoimmune neurologic diseases (Q34257903) (← links)
- Natalizumab in pediatric multiple sclerosis patients (Q34409523) (← links)
- Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option (Q34816447) (← links)
- Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. (Q34893972) (← links)
- Integrin targeted therapeutics (Q34912684) (← links)
- Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring (Q35093103) (← links)
- Immune reconstitution inflammatory syndrome in natalizumab-associated PML. (Q35215625) (← links)
- Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy (Q35675602) (← links)
- Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control (Q35758657) (← links)
- From injection therapies to natalizumab: views on the treatment of multiple sclerosis (Q35825914) (← links)
- Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis (Q35957449) (← links)
- Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case report (Q36166706) (← links)
- Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis (Q36190565) (← links)
- A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4. (Q36347678) (← links)
- Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none (Q36426562) (← links)
- Natalizumab therapy for multiple sclerosis (Q36568666) (← links)
- Disrupted balance of T cells under natalizumab treatment in multiple sclerosis. (Q36669122) (← links)
- Complications of immunosuppressive/immunomodulatory therapy in neurological diseases (Q37013065) (← links)
- New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies (Q37045253) (← links)
- Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod (Q37475542) (← links)
- The role of natalizumab in hematopoietic stem cell mobilization (Q37536053) (← links)
- Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project (Q37568787) (← links)
- Monoclonal antibodies as disease modifying therapy in multiple sclerosis. (Q37668086) (← links)
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (Q37714089) (← links)
- Update on the treatment options for multiple sclerosis (Q37729045) (← links)
- Progressive multifocal leukoencephalopathy: what's new? (Q37755922) (← links)
- Clinical pharmacokinetics of therapeutic monoclonal antibodies (Q37770555) (← links)